NCT05081245: An ongoing trial by MapLight Therapeutics
This trial is ongoing. It must report results 1 year, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05081245 |
|---|---|
| Title | A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD). |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 13, 2022 |
| Completion date | Oct. 31, 2026 |
| Required reporting date | Oct. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |